B
1.95
-0.13 (-6.25%)
| Previous Close | 2.08 |
| Open | 2.09 |
| Volume | 1,190,129 |
| Avg. Volume (3M) | 946,184 |
| Market Cap | 116,041,616 |
| Price / Book | 4.61 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Diluted EPS (TTM) | -3.54 |
| Total Debt/Equity (MRQ) | 27.58% |
| Current Ratio (MRQ) | 2.26 |
| Operating Cash Flow (TTM) | -113.53 M |
| Levered Free Cash Flow (TTM) | -74.11 M |
| Return on Assets (TTM) | -74.21% |
| Return on Equity (TTM) | -156.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Biomea Fusion, Inc. | Bullish | Bearish |
AIStockmoo Score
1.6
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.76% |
| % Held by Institutions | 45.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (D. Boral Capital, 720.51%) | Buy |
| Median | 8.50 (335.90%) | |
| Low | 5.00 (Jefferies, 156.41%) | Buy |
| Average | 9.50 (387.18%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 1.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 07 Oct 2025 | 16.00 (720.51%) | Buy | 2.15 |
| 03 Oct 2025 | 16.00 (720.51%) | Buy | 2.15 | |
| Jefferies | 28 Aug 2025 | 5.00 (156.41%) | Buy | 1.92 |
| Citigroup | 11 Aug 2025 | 7.00 (258.97%) | Buy | 1.53 |
| 16 Jul 2025 | 9.00 (361.54%) | Buy | 1.91 | |
| Scotiabank | 06 Aug 2025 | 10.00 (412.82%) | Buy | 1.59 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |